Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether administration of octreotide (12-25
mcg/hour) for 72 hours in combination with the standard of care treatment is effective in
reducing bronchorrhea (excessive airway secretions) in mechanically ventilated patients. The
use of this drug (octreotide) to manage bronchorrhea has not been approved by the United
States Food and Drug Administration (FDA) and is used as an experimental drug in this
research study. We are anticipating to enroll approximately 30 subjects in this study at
Danbury Hospital, with 15 patients randomly assigned to the "Routine Care" group, which will
serve as the control group, and 15 patients randomly assigned to the octreotide group.
Control group will only receive the standard of care and will not receive this drug. Total
subject participation in this study will be for 4 days (96 hours) or until their breathing
tube is removed (extubation), whichever occurs first.